Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.

OBJECTIVE--To study the effect of epoprostenol (prostacyclin, PGI2) given before, during, and for 36 h after coronary angioplasty on restenosis at six months and to evaluate the transcardiac gradient of platelet aggregation before and after percutaneous transluminal coronary angioplasty (PTCA) in tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gershlick, A. H., Spriggins, D., Davies, S. W., Syndercombe Court, Y. D., Timmins, J., Timmis, A. D., Rothman, M. T., Layton, C., Balcon, R.
Format: Artigo
Idioma:Inglês
Publicat: 1994
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC483601/
https://ncbi.nlm.nih.gov/pubmed/8297699
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars